piroximone has been researched along with 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobowski, G; Bristol, JA; Burke, SE; Evans, DB; Newton, RS; Sircar, I; Steffen, RP; Weishaar, RE | 1 |
| Bristol, JA; Humblet, CC; McPhail, AT; Moos, WH; Rithner, C; Sircar, I; Weishaar, RE | 1 |
| Alvarez, R; Bruno, JJ; Stephenson, RA; Strosberg, AM; Venuti, MC | 1 |
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Erhardt, PW | 1 |
2 review(s) available for piroximone and 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
3 other study(ies) available for piroximone and 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone
| Article | Year |
|---|---|
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiotonic Agents; Dogs; Female; Fibrinolytic Agents; Heart Failure; Humans; Imidazoles; Male; Myocardial Contraction; Platelet Aggregation; Pyridazines; Structure-Activity Relationship; Vasodilator Agents | 1989 |
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Myocardial Contraction; Spectrophotometry, Infrared; X-Ray Diffraction | 1987 |
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cardiotonic Agents; Dogs; Drug Evaluation; Heart Failure; Humans; Myocardium; Platelet Aggregation; Quinazolines; Structure-Activity Relationship | 1988 |